EP3139928A4 - Anordrin-zusammensetzungen und verfahren zur behandlung von krankheiten - Google Patents

Anordrin-zusammensetzungen und verfahren zur behandlung von krankheiten Download PDF

Info

Publication number
EP3139928A4
EP3139928A4 EP15788674.8A EP15788674A EP3139928A4 EP 3139928 A4 EP3139928 A4 EP 3139928A4 EP 15788674 A EP15788674 A EP 15788674A EP 3139928 A4 EP3139928 A4 EP 3139928A4
Authority
EP
European Patent Office
Prior art keywords
anordrin
compositions
methods
treating diseases
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15788674.8A
Other languages
English (en)
French (fr)
Other versions
EP3139928B1 (de
EP3139928C0 (de
EP3139928A1 (de
Inventor
Jun Yang
Huijuan Shi
Wenping Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changzhou Ruiming Pharmaceutical Company Ltd
Shanghai Institute of Planned Parenthood Research
Original Assignee
Changzhou Ruiming Pharmaceutical Company Ltd
Shanghai Institute of Planned Parenthood Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changzhou Ruiming Pharmaceutical Company Ltd, Shanghai Institute of Planned Parenthood Research filed Critical Changzhou Ruiming Pharmaceutical Company Ltd
Publication of EP3139928A1 publication Critical patent/EP3139928A1/de
Publication of EP3139928A4 publication Critical patent/EP3139928A4/de
Application granted granted Critical
Publication of EP3139928B1 publication Critical patent/EP3139928B1/de
Publication of EP3139928C0 publication Critical patent/EP3139928C0/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP15788674.8A 2014-05-08 2015-04-30 Anordrin-zusammensetzungen und verfahren zur behandlung von krankheiten Active EP3139928B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410192569.2A CN104208069A (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法
PCT/CN2015/077942 WO2015169173A1 (en) 2014-05-08 2015-04-30 Anordrin compositions and methods for treating diseases

Publications (4)

Publication Number Publication Date
EP3139928A1 EP3139928A1 (de) 2017-03-15
EP3139928A4 true EP3139928A4 (de) 2017-12-13
EP3139928B1 EP3139928B1 (de) 2025-03-05
EP3139928C0 EP3139928C0 (de) 2025-03-05

Family

ID=52090245

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15788674.8A Active EP3139928B1 (de) 2014-05-08 2015-04-30 Anordrin-zusammensetzungen und verfahren zur behandlung von krankheiten

Country Status (5)

Country Link
US (3) US10231978B2 (de)
EP (1) EP3139928B1 (de)
JP (4) JP6594339B2 (de)
CN (3) CN113101292B (de)
WO (1) WO2015169173A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113101292B (zh) 2014-05-08 2023-07-11 上海市生物医药技术研究院 双炔失碳酯组合物和疾病治疗方法
CN105279394B (zh) * 2015-10-13 2017-12-26 山西农业大学 用于神经肽受体筛选的方法
JP6788255B2 (ja) * 2015-11-19 2020-11-25 国立大学法人信州大学 新規ベクター及びこれを用いた可溶化タンパク質の製造方法
PL3525774T3 (pl) 2016-10-11 2022-04-25 Duke University Leczenie lazofoksyfenem raka piersi er+
WO2018090049A1 (en) * 2016-11-14 2018-05-17 The Brigham And Women's Hospital, Inc. Estrogen sensing through gper1 regulates normal and malignant liver growth
CN115737637A (zh) 2017-01-10 2023-03-07 王巍 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法
WO2019041078A1 (en) * 2017-08-28 2019-03-07 Zhejiang Jiachi Pharmaceutical Development Ltd. ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES
CN109662968B (zh) * 2017-10-13 2021-05-18 上海奥奇医药科技有限公司 含A-失碳-5α雄甾烷化合物的升白制剂及其应用
WO2019199891A1 (en) 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
CN111773388B (zh) * 2019-04-04 2023-07-18 上海奥奇医药科技有限公司 A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
US20210299098A1 (en) * 2020-03-31 2021-09-30 Cipla Limited Selective estrogen receptor modulator for treatment of pancreatic cancer
WO2022246634A1 (en) * 2021-05-25 2022-12-01 Zhejiang Jiachi Development Pharmaceuticals Ltd. Compositions for treating insomnia and uses thereof
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001120A (en) * 1989-05-10 1991-03-19 Natural Pharmacia International, Inc. Use of A-Nor-steroids as malignant cells growth inhibitors
WO2012136133A1 (zh) * 2011-04-08 2012-10-11 上海奥奇医药科技有限公司 A-失碳-5α-雄甾烷化合物在制备抗恶性肿瘤药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
JP2006508061A (ja) * 2002-09-20 2006-03-09 ファイザー・プロダクツ・インク エストロゲン受容体に対するアミドおよびスルホンアミドリガンド
US20050227929A1 (en) * 2003-11-13 2005-10-13 Masferrer Jaime L Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
AU2005267210A1 (en) * 2004-06-30 2006-02-02 Merck & Co., Inc. Estrogen receptor modulators
CA2626337C (en) 2005-10-19 2015-12-29 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
CN101297970A (zh) * 2006-03-17 2008-11-05 山东蓝金生物工程有限公司 同载抗代谢药物及其增效剂的抗癌缓释注射剂
US20090142337A1 (en) 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
MX2013000521A (es) 2010-07-16 2013-03-05 Merck Patent Gmbh Partido para usarse en tratamiento de cancer de mama y/o metastasis osea.
CN101987081B (zh) * 2010-07-16 2012-08-08 钟术光 一种控释制剂
AU2012229147B2 (en) 2011-03-11 2015-12-24 Merrimack Pharmaceuticals, Inc. Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
CN113101292B (zh) 2014-05-08 2023-07-11 上海市生物医药技术研究院 双炔失碳酯组合物和疾病治疗方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001120A (en) * 1989-05-10 1991-03-19 Natural Pharmacia International, Inc. Use of A-Nor-steroids as malignant cells growth inhibitors
WO2012136133A1 (zh) * 2011-04-08 2012-10-11 上海奥奇医药科技有限公司 A-失碳-5α-雄甾烷化合物在制备抗恶性肿瘤药物中的应用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2010, WENG, XIUHUA ET AL: "Comparison of the different effects between two epimerides of anordrin .alpha. and .beta. monomer on human prostatic cancer in vitro", XP002775209, retrieved from STN Database accession no. 2010:376254 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LOU, LIGUANG ET AL: "Induction of apoptosis of human leukemia cells by .alpha.-anordrin", XP002775212, retrieved from STN Database accession no. 1999:170147 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MA, ZHONGCAI ET AL: "The inhibitory effect of .alpha.-anordrin and other drugs on the growth of Swarm rat chondrosarcoma", XP002775211, retrieved from STN Database accession no. 2000:183111 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; WENG, XIUHUA ET AL: "Comparison of the effects of .alpha.-anordrin on androgen-dependent and independent human prostate cancer", XP002775210, retrieved from STN Database accession no. 2010:1411820 *
GU JIAN ET AL: "Comparison of antitumor effect of alpha-anordrin and its metabolite AF-45", TUMOR, vol. 14, no. 2, 31 March 1994 (1994-03-31), pages 66 - 69, XP055235994 *
LOU, LIJUN ET AL: "Induction of apoptosis by .alpha.-anordrin in adriamycin-resistant MCF-7", HENAN YIKE DAXUE XUEBAO ( 1999 ), 34(3), 37-39 CODEN: HEYDE2; ISSN: 1000-1069, 1999, XP009501124 *
See also references of WO2015169173A1 *
XU, BIN ET AL: ".alpha.-Anordrin (AF-53, 2.alpha., 17.alpha.-Diethynyl-A-nor-5.alpha.-androstane-2.beta., 17.beta.-diol dipropionate)", DRUGS OF THE FUTURE ( 1997 ), 22(10), 1073-1078 CODEN: DRFUD4; ISSN: 0377-8282, 1997, XP009501121, DOI: 10.1358/DOF.1997.022.10.425577 10.1358/DOF.1997.022.10.425577 *

Also Published As

Publication number Publication date
US20170151263A1 (en) 2017-06-01
CN113101292A (zh) 2021-07-13
JP2017514853A (ja) 2017-06-08
JP2022078330A (ja) 2022-05-24
EP3139928B1 (de) 2025-03-05
US10231978B2 (en) 2019-03-19
EP3139928C0 (de) 2025-03-05
CN113101292B (zh) 2023-07-11
US11911397B2 (en) 2024-02-27
JP6594339B2 (ja) 2019-10-23
US20210069212A1 (en) 2021-03-11
US20190262360A1 (en) 2019-08-29
JP2021050241A (ja) 2021-04-01
WO2015169173A1 (en) 2015-11-12
US10857158B2 (en) 2020-12-08
CN104208069A (zh) 2014-12-17
CN111956653A (zh) 2020-11-20
JP7084467B2 (ja) 2022-06-14
EP3139928A1 (de) 2017-03-15
JP2019142969A (ja) 2019-08-29
CN111956653B (zh) 2023-06-30

Similar Documents

Publication Publication Date Title
EP3096617A4 (de) Zusammensetzungen und verfahren zur behandlung von augenerkrankungen
EP3102233A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs und entzündungskrankheiten
EP3263132A4 (de) Zusammensetzung zur behandlung von il-6-assoziierten erkrankungen
EP3154566A4 (de) Verfahren und zusammensetzungen zur behandlung von geschwüren
EP3099296A4 (de) Isoindolinzusammensetzungen und verfahren zur behandlung neurodegenerativer erkrankungen
EP3139928A4 (de) Anordrin-zusammensetzungen und verfahren zur behandlung von krankheiten
EP3200815A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs
EP3209298A4 (de) Zusammensetzungen und verfahren zur behandlung von schlaflosigkeit
EP3189036A4 (de) Zusammensetzungen und verfahren zur behandlung von proliferativen erkrankungen
EP3189074A4 (de) Zusammensetzungen und verfahren zur behandlung und vorbeugung von entzündungen
EP3110446A4 (de) Verfahren und zusammensetzungen zur behandlung von siglec-8-assoziierten krankheiten
EP3134120A4 (de) Zusammensetzungen und verfahren zur behandlung von erkrankungen im zusammenhang mit cytokin
EP3148575A4 (de) Verfahren und zusammensetzungen zur behandlung von allergie- und entzündungskrankheiten
EP3310385A4 (de) Verfahren und zusammensetzungen zur behandlung von fibrotischen erkrankungen
ZA201606199B (en) Compositions and methods for treating diabetes and liver diseases
EP3240577A4 (de) Verfahren und zusammensetzungen zur behandlung von hirnerkrankungen
EP3131556A4 (de) Verfahren und zusammensetzungen zur behandlung von copd-erkrankungen
EP3142699A4 (de) Zusammensetzungen und verfahren zur behandlung von stoffwechselstörungen
EP3134733A4 (de) Zusammensetzungen und verfahren zur behandlung von patienten mit immunvermittelten erkrankungen
EP3185910A4 (de) Verfahren und zusammensetzungen zur krebsbehandlung
EP3194027A4 (de) Verfahren und zusammensetzungen zur behandlung psychotischer erkrankungen
EP3154544A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
ZA201606673B (en) Compositions and methods for treating neurodegenerative diseases
EP3164132A4 (de) Verfahren und zusammensetzungen zur behandlung von erkrankungen und leiden
EP3240533A4 (de) Zusammensetzungen und verfahren zur glaukombehandlung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20171114

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 19/10 20060101ALI20171106BHEP

Ipc: A61P 3/04 20060101ALI20171106BHEP

Ipc: A61P 1/16 20060101ALI20171106BHEP

Ipc: A61P 15/12 20060101ALI20171106BHEP

Ipc: A61P 35/00 20060101ALI20171106BHEP

Ipc: A61K 31/56 20060101AFI20171106BHEP

Ipc: A61P 3/06 20060101ALI20171106BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200212

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20241001

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015091160

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20250305

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20250311

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 11

Effective date: 20250305

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250305

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250606

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250705

REG Reference to a national code

Ref country code: CH

Ref legal event code: H13

Free format text: ST27 STATUS EVENT CODE: U-0-0-H10-H13 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250305

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: CH

Ref legal event code: L10

Free format text: ST27 STATUS EVENT CODE: U-0-0-L10-L00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250430

26N No opposition filed

Effective date: 20251208